We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+18.11%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.07B
AUM Growth
+$214M
Cap. Flow
+$110M
Cap. Flow %
10.26%
Top 10 Hldgs %
29.29%
Holding
121
New
28
Increased
49
Reduced
15
Closed
16

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$25.5M
2
RDUS
Radius Health, Inc.
RDUS
+$18M
3
LLY icon
Eli Lilly
LLY
+$16.4M
4
BHC icon
Bausch Health
BHC
+$16.3M
5
TMO icon
Thermo Fisher Scientific
TMO
+$12.9M

Top Sells

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$30.2M
2
MRK icon
Merck
MRK
+$25.6M
3
STJ
St Jude Medical
STJ
+$21.8M
4
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$18.6M
5
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 75.22%
2 Financials 1.56%
3 Industrials 0.97%
4 Technology 0.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ROKA
101
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$800K 0.07%
25,000
– –
ETRM
102
DELISTED
EnteroMedics Inc.
ETRM
$743K 0.07%
773
-298
-28% -$359K
DERM
103
DELISTED
Dermira, Inc.
DERM
$649K 0.06%
42,274
-45,000
-52% -$756K
ASND icon
104
Ascendis Pharma A/S
ASND
$16.8B
$617K 0.06%
+35,540
New +$646K
HRTX icon
105
Heron Therapeutics
HRTX
$92.9M
$473K 0.04%
32,500
-127,500
-80% -$1.44M
COR icon
106
Cencora
COR
$61.2B
– –
-80,000
Closed -$7.21M
MRK icon
107
Merck
MRK
$318B
– –
-471,600
Closed -$25.6M
CTLT
108
DELISTED
CATALENT, INC.
CTLT
– –
-133,600
Closed -$3.73M
CBAY
109
DELISTED
Cymabay Therapeutics
CBAY
– –
-100,000
Closed -$983K
RAD
110
DELISTED
Rite Aid Corporation
RAD
– –
-45,865
Closed -$6.9M
BLCM
111
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-3,500
Closed -$806K
HRC
112
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
– –
-225,000
Closed -$10.3M
PFNX
113
DELISTED
Pfenex Inc.
PFNX
– –
-328,100
Closed -$2.4M
STJ
114
DELISTED
St Jude Medical
STJ
– –
-335,000
Closed -$21.8M
CYBX
115
DELISTED
CYBERONICS INC
CYBX
– –
-68,000
Closed -$3.79M
SLXP
116
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
– –
-77,500
Closed -$8.91M
MWIV
117
DELISTED
MWI VETERINARY SUPPLY, INC.
MWIV
– –
-39,000
Closed -$6.63M
CBST
118
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
– –
-87,500
Closed -$8.81M
AVNR
119
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
– –
-1,100,000
Closed -$18.6M
COV
120
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
– –
-295,000
Closed -$30.2M
AGN
121
DELISTED
Allergan Inc
AGN
– –
-18,500
Closed -$3.93M
1 2 3 4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2015 Portfolio in Review

As of Q1 2015, Rock Springs Capital Management held 121 positions worth $1.07B, up 25% from $855M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management deployed $110M of net new capital in Q1 2015, opening 28 new positions and adding to 49 existing holdings. Its largest new stake was Pfizer: 801,040 shares worth $26.4M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 73% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Avadel Pharmaceuticals, an estimated $3.37M trimmed.

  • Rock Springs Capital Management's largest Q1 2015 buy was Pfizer: 801,040 shares worth $26.4M.
  • Rock Springs Capital Management added most to Bausch Health in Q1 2015, an estimated $16.3M increase.
  • Rock Springs Capital Management's biggest Q1 2015 reduction was Avadel Pharmaceuticals, cutting an estimated $3.37M.
  • Rock Springs Capital Management fully exited COVIDIEN PLC COM SHS NEW (IRELAND) in Q1 2015, selling an estimated $30.2M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $1.07B portfolio in Q1 2015.
  • Rock Springs Capital Management opened 28 new positions and closed 16 in Q1 2015.
  • Rock Springs Capital Management's portfolio value rose 25% quarter-over-quarter to $1.07B.

Based on Rock Springs Capital Management's 13F filing for Q1 2015, filed 15 May 2015.